Compare GSK plc (GSK) vs ArcelorMittal SA (MT) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

ArcelorMittal (MT) trades at $66.99, up 1.62% today, with strong technical momentum and bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.17. Revenue declined from $79.8B in 2022 to $61.4B in 2025, but net income improved to $3.2B, reflecting margin expansion. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks.

The outlook remains positive with analyst consensus favoring Buy ratings (50%), though risks include declining revenue trends and heavy capital expenditures. The stock's valuation appears reasonable with P/E of 17.7 and P/B of 0.92, trading below book value. Key catalysts include steel import controls in Europe and expansion projects, while headwinds involve China weakness and decarbonization costs.